Guohua Zhao
About Guohua Zhao
Guohua Zhao is a Principal Scientist at Bristol Myers Squibb in Princeton, New Jersey, with extensive experience in drug discovery and medicinal chemistry.
Company
Guohua Zhao is currently working at Bristol Myers Squibb as a Principal Scientist. His professional journey at the company has spanned various roles, starting from Research Investigator I to his current position. His experiences at Bristol Myers Squibb have centered around medicinal chemistry and drug discovery.
Title and Roles
Guohua Zhao serves as a Principal Scientist at Bristol Myers Squibb in Princeton, New Jersey. He began his career at the company in 1998 as a Research Investigator I before progressing through several roles, including Research Investigator II, Senior Research Investigator I, and Senior Research Investigator II. His tenure at the company includes significant contributions and leadership in drug discovery programs.
Contributions to Drug Discovery
Guohua Zhao has led or engaged in 16 early/ full phase drug discovery programs, resulting in 8 clinical candidates. Notably, he was responsible for the discovery of the MCHR1 clinical candidate BMS-950458. He has also been a key contributor to three other clinical candidates, including the DPP4 inhibitor that ultimately resulted in the marketed drug Onglyza.
Expertise in Medicinal Chemistry
Guohua Zhao possesses extensive experience in medicinal chemistry, particularly in cardiovascular, metabolic diseases, obesity (CNS), and fibrosis drug discovery. His knowledge spans various critical areas, including ADME/PK, toxicology, pharmaceutics, and computational chemistry. His technical expertise has enabled significant advancements in drug discovery.
Publications and Patents
Guohua Zhao is an author or coauthor of 20 scientific publications and 20 presentations. He is also a co-inventor on 21 patents or patent applications. His work has defined patent strategies and involved drafting patents. These accomplishments underscore his significant contributions to scientific research and intellectual property in his field.